Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
2004 2
2005 3
2006 2
2007 2
2008 2
2009 7
2010 5
2011 8
2012 5
2013 9
2014 7
2015 2
2016 6
2017 5
2018 6
2019 6
2020 6
2021 3
2022 7
2023 1
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

80 results

Results by year

Filters applied: . Clear all
Page 1
Pilot randomized controlled trial of a program to enhance experience and adherence with adjuvant endocrine therapy among women with non-metastatic breast cancer: 12-month quantitative results.
Assan O, Memoli V, Guillaumie L, Turcotte V, Lemay M, Dionne A, Lemieux J, Provencher L, Gotay C, de Bruin M, Guénette L, Lauzier S. Assan O, et al. Among authors: provencher l. J Cancer Surviv. 2024 May 4. doi: 10.1007/s11764-024-01599-y. Online ahead of print. J Cancer Surviv. 2024. PMID: 38702555
Third-line treatment patterns in HER2-positive metastatic breast cancer: a retrospective analysis of real-world data in Canada.
Gambaro K, Groleau M, McNamara S, Awan A, Salem M, Abdelsalam M, St-Hilaire E, Vincent F, Carrier J, MacKay H, Provencher L, Boudreau D, Hamilou Z, Saad F, Ferrario C, Batist G, Marques M. Gambaro K, et al. Among authors: provencher l. J Pharm Pharm Sci. 2023 Dec 13;26:12078. doi: 10.3389/jpps.2023.12078. eCollection 2023. J Pharm Pharm Sci. 2023. PMID: 38152647 Free PMC article.
A Phase I/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor-positive/HER2-negative Advanced or Metastatic Breast Cancer.
Cescon DW, Hilton J, Morales Murilo S, Layman RM, Pluard T, Yeo B, Park IH, Provencher L, Kim SB, Im YH, Wyce A, Krishnatry AS, Hicks K, Zhang Q, Barbash O, Khaled A, Horner T, Dhar A, Oliveira M, Sparano JA. Cescon DW, et al. Among authors: provencher l. Clin Cancer Res. 2024 Jan 17;30(2):334-343. doi: 10.1158/1078-0432.CCR-23-0133. Clin Cancer Res. 2024. PMID: 37992310 Free PMC article. Clinical Trial.
Impact of the 21-Gene Recurrence Score Assay on Treatment Decisions and Cost in Patients with Node-Positive Breast Cancer: A Multicenter Study in Quebec.
Hassan S, Younan R, Patocskai E, Provencher L, Poirier B, Sideris L, Dubé P, Mihalcioiu C, Chabot-Blanchet M, Guertin MC, Boileau JF, Robidoux A. Hassan S, et al. Among authors: provencher l. Oncologist. 2022 Oct 1;27(10):822-831. doi: 10.1093/oncolo/oyac123. Oncologist. 2022. PMID: 35830543 Free PMC article.
Correction to: Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology).
Geyer CE Jr, Bandos H, Rastogi P, Jacobs SA, Robidoux A, Fehrenbacher L, Ward PJ, Polikoff J, Brufsky AM, Provencher L, Paterson AHG, Hamm JT, Carolla RL, Baez-Diaz L, Julian TB, Swain SM, Mamounas EP, Wolmark N. Geyer CE Jr, et al. Among authors: provencher l. Breast Cancer Res Treat. 2022 Jun;193(3):565. doi: 10.1007/s10549-022-06613-4. Breast Cancer Res Treat. 2022. PMID: 35507135 Free PMC article. No abstract available.
Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology).
Geyer CE Jr, Bandos H, Rastogi P, Jacobs SA, Robidoux A, Fehrenbacher L, Ward PJ, Polikoff J, Brufsky AM, Provencher L, Paterson AHG, Hamm JT, Carolla RL, Baez-Diaz L, Julian TB, Swain SM, Mamounas EP, Wolmark N. Geyer CE Jr, et al. Among authors: provencher l. Breast Cancer Res Treat. 2022 Jun;193(3):555-564. doi: 10.1007/s10549-021-06417-y. Epub 2022 Mar 1. Breast Cancer Res Treat. 2022. PMID: 35230585 Free PMC article.
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.
Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Untch M, Fasching PA, Cardoso F, Andersen J, Patt D, Danso M, Ferreira M, Mouret-Reynier MA, Im SA, Ahn JH, Gion M, Baron-Hay S, Boileau JF, Ding Y, Tryfonidis K, Aktan G, Karantza V, O'Shaughnessy J; KEYNOTE-522 Investigators. Schmid P, et al. N Engl J Med. 2022 Feb 10;386(6):556-567. doi: 10.1056/NEJMoa2112651. N Engl J Med. 2022. PMID: 35139274 Clinical Trial.
Women with breast cancer's perceptions of nurse-led telephone-based motivational interviewing consultations to enhance adherence to adjuvant endocrine therapy: a qualitative study.
Gagné M, Lauzier S, Lemay M, Loiselle CG, Provencher L, Simard C, Guillaumie L. Gagné M, et al. Among authors: provencher l. Support Care Cancer. 2022 Jun;30(6):4759-4768. doi: 10.1007/s00520-021-06692-x. Epub 2022 Feb 8. Support Care Cancer. 2022. PMID: 35133477 Free PMC article.
Behavioral and health outcomes from the NRG Oncology/NSABP B-36 trial comparing two different adjuvant therapy regimens for early-stage node-negative breast cancer.
Ganz PA, Bandos H, Geyer CE Jr, Robidoux A, Paterson AHG, Polikoff J, Baez-Diaz L, Brufsky AM, Fehrenbacher L, Parsons AW, Ward PJ, Provencher L, Hamm JT, Stella PJ, Carolla RL, Margolese RG, Shibata HR, Perez EA, Wolmark N. Ganz PA, et al. Among authors: provencher l. Breast Cancer Res Treat. 2022 Feb;192(1):153-161. doi: 10.1007/s10549-021-06475-2. Epub 2022 Feb 3. Breast Cancer Res Treat. 2022. PMID: 35112166 Free PMC article. Clinical Trial.
80 results